GlassScriptPhysician profile
Thomas Middour
NPI 1841618311
$24,999.97
in general payments reported to CMS, 2019-2025
24 companies · $2,937 in 2025
The $2,937 reported for 2025 was more than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,112 · 2020: $40.50 · 2021: $11K · 2022: $4,663 · 2023: $1,338 · 2024: $3,211 · 2025: $2,937.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,358 · Travel and Lodging: $1,129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,357.57 |
| Travel and Lodging | $1,128.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $10,887.14 | 2021-2025 | Affera Mapping System, Aurora Ev-Icd Mri Surescan |
| Abbott Laboratories | $6,566.43 | 2019-2025 | Aveir, Ensite Precision, Ensite |
| Boston Scientific Corporation | $2,022.89 | 2021-2025 | Farapulse, Watchman Flx, Cds Broad Portfolio Offering |
| Biotronik INC. | $1,654.21 | 2022-2024 | Selectra |
| Biosense Webster, INC. | $948.15 | 2022-2025 | Carto 3, Qdot Micro Catheter, Nuvision Ice Catheter |
| Medical Device Business Services, INC. | $917.18 | 2024 | Carto 3 |
| Cardiva Medical, INC. | $343.29 | 2022-2025 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade Mvp Xl Vvcs 10-12f |
| Astrazeneca Pharmaceuticals LP | $322.75 | 2019-2024 | Farxiga |
| Angiodynamics, INC. | $177.21 | 2024-2025 | Alphavac |
| Amgen INC. | $172.75 | 2019-2024 | Repatha |
| Atricure, INC. | $166.54 | 2022 | |
| Cvrx, INC. | $130.41 | 2023-2025 | Barostim Neo System |
| Lantheus Medical Imaging, INC. | $124.16 | 2019 | |
| Pfizer INC. | $109.96 | 2019-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $107.66 | 2023-2025 | Lifevest |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $80.95 | 2023-2025 | Verquvo |
| Abiomed | $59.48 | 2024-2025 | Impella |
| Innovation Technologies INC | $45.78 | 2025 | Irrisept |
| Heartflow, INC. | $40.37 | 2023-2024 | Ffrct |
| Janssen Pharmaceuticals, INC | $37.66 | 2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $22.94 | 2024 | |
| Bridgebio Pharma, INC. | $22.64 | 2025 | Attruby |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.87 | 2023 | Jardiance |
| Edwards Lifesciences Corporation | $18.55 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Middour listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.